摘要
Mycoplasma pneumoniae is a major etiological agent of communityacquired pneumonia that accounts for 10%to 40%of communityacquired pneumonia and exhibits distinct cyclic epidemic patterns that recur at 3-to 7-year intervals,[1-4] Nonpharmaceutical interventions(NPIs)against coronavirus disease 2019(COVID-19)that were used by countries worldwide during the pandemic significantly reduced the prevalence of M.pneumoniae.[5]After the lifting of COVID-19 pandemic restrictions,M.pneumoniae gradually grew globally.[6]To provide a better understanding of the growth of M.pneumoniae in 2023,we explored the hazards,incidence,diagnosis,and antibiotic resistance of M.pneumoniae.
基金
the National Key R&D Program of China(2021ZD0114103)
the Capital's Funds for Health Improvement and Research(2022-4G-30117).
